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Interaction of Cyclin-Dependent Kinase 12/CrkRS with Cyclin K1 Is
Required for the Phosphorylation of the C-Terminal Domain of RNA
Polymerase II
S.-W. Grace Cheng,a Michael A. Kuzyk,a,b Annie Moradian,a Taka-Aki Ichu,a Vicky C.-D. Chang,a Jerry F. Tien,a,c Sarah E. Vollett,a
Malachi Grifﬁth,a,d Marco A. Marra,a,e and Gregg B. Morina,e
Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canadaa; GenoLogics, Victoria, British Columbia, Canadab;
Department of Biochemistry, University of Washington, Seattle, Washington, USAc; The Genome Institute, Washington University School of Medicine, St. Louis, Missouri,
USAd; and Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canadae
CrkRS (Cdc2-related kinase, Arg/Ser), or cyclin-dependent kinase 12 (CKD12), is a serine/threonine kinase believed to coordi-
nate transcription and RNA splicing. While CDK12/CrkRS complexes were known to phosphorylate the C-terminal domain
(CTD) of RNA polymerase II (RNA Pol II), the cyclin regulating this activity was not known. Using immunoprecipitation and
mass spectrometry, we identified a 65-kDa isoform of cyclin K (cyclin K1) in endogenous CDK12/CrkRS protein complexes. We
show that cyclin K1 complexes isolated frommammalian cells contain CDK12/CrkRS but do not contain CDK9, a presumed
partner of cyclin K. Analysis of extensive RNA-Seq data shows that the 65-kDa cyclin K1 isoform is the predominantly expressed
form across numerous tissue types. We also demonstrate that CDK12/CrkRS is dependent on cyclin K1 for its kinase activity and
that small interfering RNA (siRNA) knockdown of CDK12/CrkRS or cyclin K1 has similar effects on the expression of a lucifer-
ase reporter gene. Our data suggest that cyclin K1 is the primary cyclin partner for CDK12/CrkRS and that cyclin K1 is required
to activate CDK12/CrkRS to phosphorylate the CTD of RNA Pol II. These properties are consistent with a role of CDK12/CrkRS
in regulating gene expression through phosphorylation of RNA Pol II.
Cyclin-dependent kinases (CDKs) regulate a variety of cellularprocesses, including cell cycle progression, transcription, and
RNA processing (52). Their activity requires heterodimeric inter-
actions with specific cyclins where the CDK is the catalytic subunit
and the cyclin is the regulatory subunit (52). CDKs/cyclins typi-
cally are the nexus of signal transduction pathways for the regula-
tion of central cellular processes.
Many of the20 humanCDKs, such as CDK1, -2, -3, -4, -5, -6,
-10, and -11p58, which partner withmembers of the cyclin A, B, C,
D, and E families, are involved in cell cycle progression (3, 43, 52).
Cyclins A, B, D, and E, which interact with CDK1, -2, -3, and -6,
show fluctuating expression levels during different phases of the
cell cycle (25). CDK7, -8, -9, and -11 are involved in transcrip-
tional regulation (20). CDK9, CDK11p110, CDK12/CrkRS (Cdc2-
related kinase, Arg/Ser), andCDK13/CDC2L5 have been reported
to have roles in both transcription and pre-mRNA processing (4,
6, 9, 10, 19, 26, 37, 38). Themultiple functions of CDKs are due, in
part, to their interactions with different cyclin partners which
modulate their localization and activity (15, 42, 67).
Previous studies have demonstrated a link between transcrip-
tion and pre-mRNA processing (29, 45, 47). The multisubunit
RNA polymerase II (RNA Pol II) links transcription and cotrans-
criptional maturation of pre-mRNA through differential recruit-
ment of transcription and RNA processing factors to the C-termi-
nal domain (CTD) of its largest subunit, Rbp1 (24, 37). The
integration of these twoprocesses is tightly regulated by posttrans-
lational modification of the CTD. CDK7, -8, and -9 differentially
phosphorylate the amino acid residues in the heptad repeat of the
CTD to regulate the activation of elongation during transcription.
The CTD, which in humans consists of 52 tandem heptaresidue
repeats with a consensus sequence of Tyr1Ser2Pro3Thr4Ser5
Pro6Ser7, serves as the recognition platform for interaction with a
variety of transcription factors, cofactors, and pre-mRNA pro-
cessing factors (18, 37).
In mammals, positive transcription elongation factor b (P-
TEFb) complexes are composed of CDK9 as the catalytic subunit
and one of the cyclins T1, T2a, T2b, or K (48). The ratio of two
CDK9 isoforms, CDK9p42 and CDK9p55, generated through alter-
native transcription start sites (56, 57), is different in various tis-
sues and changes when cells are challenged by different stimuli
(40, 56). Both CDK9 isoforms interact with cyclins T1, T2a/b, and
K; these different CDK9/cyclin heterodimers add cellular func-
tional complexity to P-TEFb complexes (15, 23, 53, 58, 65, 67).
For example, interaction of CDK9p42/cyclin T1 with the viral Tat
protein facilitates the transactivation of the long terminal repeat of
human immunodeficiency virus type 1 (HIV-1) andHIV-2 and is
essential for productive viral replication (22). Recently, cyclin K
was found to inhibit HIV-1 gene expression and replication
through its interaction with HIV-1 Nef (32). CDK9/cyclin T2
complexes interact with PKN and Rho-activated Ser/Thr kinase
and are involved in regulating terminal differentiation in muscle
cells through activation of Myo-D (12, 58). CDK9/cyclin K com-
plexes have also been proposed to function in replication stress
response tomaintain genome integrity (65). Thus, the interaction
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of CDK9 with specific cyclins modulates CDK9 kinase activity to
effect different cellular outcomes (15, 65, 67).
Cyclin K was originally identified as a 357-residue protein that
restores cell cycle progression and rescues the lethality of deletions
of theG1 cyclins CLN1, CLN2, andCLN3 in Saccharomyces cerevi-
siae (17). Cyclin K was independently identified in a yeast two-
hybrid screen for interactors of human CDK9 (23). CDK9/cyclin
K complexes can phosphorylate the CTD of RNA Pol II in vitro
and can functionally substitute for CDK9/cyclin T1 in in vitro
transcription assays (17, 23, 39). More recent studies have sug-
gested that a larger isoform of cyclin K interacts with CDK12 and
CDK13 (6, 13). Although many aspects of cyclin K function re-
main to be elucidated, it appears that its gene can be regulated by
p53 and that it can function in DNA damage response and endo-
derm development (6, 46, 65, 67).
CTD kinases are evolutionarily conserved in eukaryotes. In S.
cerevisiae, there are two CDK homologs with high similarity to
CDK9; the Ctk1/Ctk2 (CTDK-1) complex and the Bur1/Bur2
complex (7, 49, 64). It was assumed that CDK9 performs the func-
tions of CTDK-1 and Bur1 in higher eukaryotes (63). However,
phylogenetic studies suggest that Bur1 is homologous with CDK9,
while Ctk1 is homologous with CDK12/CrkRS and CDK13/
CDC2L5 (28, 41). Supporting this observation, it was recently
shown that Drosophila melanogaster CDK12/cyclin K appears to
be a transcription elongation phase CTD kinase (4). Although the
kinase domains of CDK12/CrkRS and CDK13/CDC2L5 are very
similar to that of Ctk-1,DrosophilaCDK12 (dCDK12) and human
CDK12/CrkRS and CDK13/CDC2L5 are much larger proteins
with additional structural features that suggest functions in signal
transduction and pre-mRNA processing. Both CDK12/CrkRS
and CDK13/CDC2L5 have N-terminal arginine/serine (RS) do-
mains which are frequently found in the SR family of RNA pro-
cessing factors (35, 55). In addition, they contain proline-rich re-
gions and several potential SRC homology 3 (SH3) domains, both
of which could recruit protein interaction partners (35). SH3 do-
mains are well-characterized protein interaction modules fre-
quently found in proteins that are involved in signaling pathways
regulating a wide variety of biological functions (44). Previous
studies have shown that dCDK12 and human CDK12/CrkRS and
CDK13/CDC2L5 can phosphorylate the CTD of RNA Pol II and
that CDK12/CrkRS colocalizes with a hyperphosphorylated form
of RNA Pol II (4, 35). Coexpression experiments suggested that
CDK12/CrkRS andCDK13/CDC2L5 can interactwith cyclin L, an
RS domain-containing cyclin, to facilitate alternative splicing of a
model substrate (9, 10). CDK13/CDC2L5 has been shown to in-
teract with ASF/SF2 to affect pre-RNA splicing in vivo (19). These
observations make CrkRS/CDK12 and CDK13/CDC2L5 well
suited for the regulation and coordination of transcription and
pre-mRNA processing.
We employed immunoprecipitation-mass spectrometry (IP-
MS) in an unbiased approach to study CDK/cyclin interactions of
CDK12/CrkRS, CDK9, and CDK11p110. We provide transcrip-
tome and protein evidence by mass spectrometry for the expres-
sion of a 65-kDa form of cyclin K in human-derived cell lines. We
also employ data from enzymatic, small interfering RNA (siRNA),
and promoter-reporter assays to establish that CDK12/CrkRS
functionally requires cyclin K1 to activate its CDK kinase func-
tions.
MATERIALS AND METHODS
Plasmids and RT-PCR. CDK12 isoform 1 (GenBank accession number
NM_016507.2), CDK9 (GenBank accession number NM_001261.3), cy-
clin L1 (GenBank accession number NM_020307.2), and cyclin K2
(GenBank accession number NM_003858.3) were obtained from the
Mammalian Gene Collection through Open Biosystems and cloned into
the Creator System (11). cDNAs were then transferred by Cre recombi-
nation into mammalian expression vectors with 3FLAG or double Myc
(dMyc) epitope tags. Cyclin T1 cDNAwas generated by reverse transcrip-
tion (RT)-PCR (RT-PCR kit, catalog number 12574-030; Invitrogen)
fromHeLa total RNA (Ambion; catalog numberAM7852) using cyclin T1
primers 5=-CTGCCTTCTGGTTGAAGCAC-3= and 5=-CTTAGGAAGG
GGTGGAAGTGGTG-3=. The cyclin T1 sequence we obtained matched
the cyclin T1 reference sequence (GenBank sequence accession number
NM_001240.2). The cyclin K1 cDNAwas also generated by RT-PCR from
HeLa mRNA using primers designed to the 5= ATG start site (primer 3,
5=-ATGAAGGAGAATAAAGAAAATTC-3=) and the 3= untranslated re-
gion (UTR) (primer 2, 5=-TACCCTGCTGCTTACCCACT-3=). To distin-
guish between cyclin K1 and cyclin K2 isoform cDNAs, RT-PCR primer 1
(5=-CATCTGCCACCAAATCCTG-3=) was used. The cyclin T1 and K1
cDNAs were cloned into the Creator System as described above and ex-
pressed in mammalian cells with either a 3FLAG or dMyc epitope tag.
RNA Pol II CTD cDNA was generated by RT-PCR using HeLa total RNA
(Ambion; catalog number AM7852) with primers 5=-GCCATGTCTCCC
AGCTACTCG-3= and 5=-TCAGTTCTCCTCGTCACTGTCATC-3= and
cloned into a glutathione S-transferase (GST) expression vector (Creator
System plasmid V1544) for bacterial expression (GST-CTD).
Mammalian cell culture. HEK293A and HeLa cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal bovine
serum (FBS). K562 cells (a gift fromX. Jiang) were cultured in RPMI, 10%
FBS, 104 M -mercaptoethanol. PTX0002 and V180 cell lines were gen-
erated by stable transfection of plasmids expressing 3FLAG-CDK12 iso-
form 1 or 3FLAG alone, respectively, into HEK293A cells.
Bacterial culture andGST-CTDpurification.TheGST-CTDplasmid
was transformed into BL21(DE3)pLysS Escherichia coli cells (Invitrogen)
and cultured in LB medium at 37°C until mid-log phase. Cells were in-
duced with 1 mM isopropyl--D-thiogalactopyranoside (IPTG) for 3 h at
37°C and harvested. Cells were lysed as previously described (35), and
GST-CTDwas purified using a 1-ml GSTrap 4B column (GEHealthcare).
Antibodies. CDK12 antibodies were obtained from J. Pines (35) and
Novus Biologicals (NB100-07001, H00051755-MO2A). Anti-FLAG anti-
body was purchased from Sigma (F1804). Anti-Myc antibodies were pur-
chased fromRoche (11667149001). CDK9 (sc-7331), cyclin T1 (sc-8127),
and CDK11 (sc-928) antibodies were purchased from Santa Cruz Bio-
technology. RNA Pol II CTD antibodies were purchased from Covance
(anti-Ser2P H5, anti-Ser5P H14, and anti-CTD 8WG16).
Immunoprecipitation and mass spectrometry. Plasmids expressing
3FLAG-tagged CDKs or cyclins were transfected using calcium phos-
phate intoHEK293A cells. At 60 h posttransfection, 108 cells were isolated
and lysed in MS lysis buffer (Tris-buffered saline [TBS], pH 7.5, 1 mM
EDTA, 0.1% NP-40, 0.05% [wt/vol] deoxycholate, 10 mM -glycero-
phosphate, 2 mM NaVO4, and Roche Complete EDTA-free protease in-
hibitors). Protein lysates were clarified by centrifugation at 13,000 rpm for
30 min at 4°C, precleared with 50 l packed Sepharose 4B beads, and
mixed overnight with 20 l packed M2-FLAG-agarose (Sigma) at 4°C.
Bound protein complexes were washed 5 times with MS lysis buffer and
once with 50 mM ammonium bicarbonate. Anti-FLAG antibody-immu-
noprecipitated complexes were eluted with 3FLAG peptide (400 ng/ml)
at room temperature for 30 min or by boiling in 2 SDS-PAGE Laemmli
sample buffer. Protein complexes eluted with 3FLAG peptide were ly-
ophilized and resuspended in SDS-PAGE sample buffer. Immunoprecipi-
tation of endogenous proteins was performed essentially as described
above, using 10 to 20 g of antibody protein G-agarose (GE Healthcare),
and eluted by boiling in 2 SDS-PAGE Laemmli sample buffer. The pro-
tein complexes were then resolved by SDS-PAGE (4 to 12% bis-Tris; In-
Cheng et al.
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vitrogen) and stainedwith colloidal Coomassie stain (8% [wt/vol] ammo-
nium sulfate, 1.6% [vol/vol] phosphoric acid, 0.08% [wt/vol] Coomassie
G-250, 20% [vol/vol] methanol). Each lane was then cut into 16 gel slices,
with each slice corresponding to a known molecular weight range, and
subjected to in-gel trypsin digestion (34).
High-performance liquid chromatography–electrospray ionization–
mass spectrometry (HPLC-ESI-MS) was performed on a 4000 QTrap
mass spectrometer (Applied Biosystems/Sciex) coupled to an Agilent
1100 Nano-HPLC using a nano-ESI interface. Samples were desalted us-
ing an on-line trap column (Zorbax 300SB-C18, 5 m, 5 by 0.3 mm;
Agilent), and chromatography coupled to electrospray ionization was
performed on a 75-m by 150-mm reverse-phase column (Reprosil-Pur
C18; Dr.Maisch GmbH) using buffer A (5% HPLC grade acetonitrile,
0.1% formic acid) and buffer B (90% acetonitrile, 0.1% formic acid) in a
linear gradient of 0 to 20% B for 23 min, 20 to 39% B for 9 min at a flow
rate of 300 nl/min. TandemMS (MS-MS) spectrum assignment was per-
formed using X!Tandem (http://www.thegpm.org/TANDEM/) andMas-
cot (Matrix Science) software against the IPI human protein database
(http://www.uniprot.org). HEK293A cells transfected with empty vector
constructs or prebleed IgG were used as negative-control samples.
RNA-Seq analysis of cyclin K gene exon and exon-exon junction
expression. RNA-Seq data of mRNA libraries available at the Michael
Smith Genome Sciences Centre production-scale sequencing facility
(British Columbia Cancer Research Centre, Vancouver British Columbia,
Canada; http://www.bcgsc.ca/platform/sequencing/) were analyzed for
cyclin K mRNA structure using two methods (see below). The libraries
were prepared using standardized protocols similar to those described in
Griffith et al. (27) and varied for read length and lanes of Illumina GAII
sequencing obtained.
ALEXA-Seq method. Using the ALEXA-Seq analysis algorithm (27)
(http://www.alexaplatform.org/), 291 lanes of paired-end reads of Illu-
mina GAII RNA-Seq data from 38 human tissues and cell lines were
mapped to a database of all possible theoretically valid exons and exon-
exon junctions of known Ensembl (21) (http://www.ensembl.org/) (ver-
sion 49) genes. Specifically, the donor sites of each known exon in a gene
were connected to all known downstream acceptor sites of the gene.
Across the 38 libraries, a total of 5.06 billion reads were mapped, of which
321,890 reads mapped to cyclin K gene exons and exon-exon junctions.
Differential expression values for the gene features were determined as the
log2 difference in average coverage values and normalized for library read
depth as described previously (27). The type and distribution of the 38
human RNA-Seq libraries were as follows: A, tumors, 24 (7 neuroblas-
toma, 6 oligodendroglioma, 5 lymphoma, 4 multiple myeloma, and 2
colorectal); and B, normal tissues, 14 (6 breast, 5 B cell, 2 brain, and 1
human embryonic stem cell [hESC]).
HMMSplicer method. A total of 1,774 lanes of paired-end Illumina
GAII RNA-Seq data from 599 human tissues and cell lines were processed
using the splice-aware aligner HMMSplicer (16) to identify expressed
canonical (GU-AG, GC-AG, and AU-CA) and noncanonical exon-exon
junctions and the read count and confidence score associated with each.
HMMSplicer does not rely on existing annotation and is capable of find-
ing novel splicing events. A total of 4.32 billion readswere found tomap to
693,238 exon-exon junctions (at least 10 reads across all libraries). Each
library yielded, on average, 129,644 distinct exon-exon junctions (with
1 observation). Of the 314,935 known junctions in our database,
223,714 (71%) were detected in at least one library (and with 10 reads
across all libraries); exon junctionswith10 reads across all libraries were
removed. Exon junction reads that mapped to the cyclin K gene were
identified; libraries with 20 total cyclin K gene junction reads were re-
moved. Across the remaining 570 libraries, there were 552,300 total
cyclin K gene exon-exon junction reads (mean 	 969, median 	 593,
and range 	 20 to 20,425); 98.3% were canonical GU-AG junctions.
There were 34 intragenic junctions (average HMMSplicer score	 1,123)
of which 10 mapped to the cyclin K1 mRNA structure (average score 	
1,373). The final types and distribution of the 570 humanRNA-Seq librar-
ies used were as follows: A, tumors, 206 (88 ovarian, 89 breast, 8 gastro-
intestinal, 6 brain, 4 colon, 4 kidney, 4 lung, 2 melanoma, and 1 urinary);
B, leukemias, 189 (170 acute myeloid leukemia [AML], 13 acute lympho-
blastic leukemia [ALL], and 6 undetermined); C, lymphomas, 116 (93
diffuse large B-cell lymphoma [DLBCL], 18 undetermined, and 5 follicu-
lar lymphoma [FL]); D, normal tissues, 37 (9 tonsil, 6 breast, 2 blood, and
1 each adipose, adrenal, bone marrow, brain, colon, heart, hESC, kidney,
liver, lung, lymph, muscle, ovary, prostate, testes, thyroid, and white
blood cell); E, other cancers, 13; F, other, 7; and G, cancer cell lines, 2.
Immunoprecipitation and Western blotting. Plasmids expressing
3FLAG-CDK12 or 3FLAG-CDK9 were cotransfected using calcium
phosphate in combination with plasmids expressing dMyc-cyclin K1, K2,
T1, and L1 into HEK293A cells. Protein complexes were prepared as de-
scribed above and immunoprecipitated with anti-FLAG or anti-Myc an-
tibodies, and Western blots were probed with anti-Myc or anti-FLAG
antibodies, respectively. MultiGauge (FujiFilm) was used to quantify
bands.
siRNA knockdown and CTD phosphorylation assay. An amount of
6  106 PTX0002 cells (stably expressing 3FLAG-CDK12) was trans-
fected with 1.2 mol of an equimolar mixture of two siRNA sequences
designed against two different regions of the 3= UTR of the cyclin K gene
(CCNK) (see Table S1 in the supplementalmaterial) or a negative-control
siRNA (catalog number 12935200; Invitrogen) using XtremeGene siRNA
transfection reagent (Roche). Twenty-four hours later, the cells were
transfected with 10 g of plasmids expressing dMyc-cyclin K1 or an
empty plasmid using Lipofectamine 2000 (Invitrogen). The medium was
changed 6 h posttransfection, and cells were harvested at 72 h post-siRNA
transfection. Twenty-five percent of the cells were used to prepare total
RNA for quantitative (qPCR) (see below), and 75% of the cells were used
to prepare protein lysates. Protein lysates were clarified and precleared
with Sepharose 4B (Sigma) as described above and incubated with 5g of
anti-FLAG antibody overnight at 4°Cwith constant rotation. Anti-FLAG-
bound 3FLAG-CDK12 protein complexes were precipitated with 20 l
packed protein G-agarose (GE Healthcare) for 30 min at 4°C and washed
5 times withMS lysis buffer, followed by 2 washes with kinase assay buffer
(50 mM Tris, pH 7.5, 100 mM NaCl, 10 mM MgCl2, 0.1% [vol/vol] NP-
40, 1mMdithiothreitol [DTT], 20M-glycerophosphate, Roche Com-
plete EDTA-free protease inhibitors). After the last wash, protein-bound
beads were resuspended in 30l kinase buffer supplemented with 50M
ATP, 1 g of purified GST-CTD, and 10 Ci of [
-32P]ATP and incu-
bated at 30°C for 1 h, and then the kinase reaction was stopped with the
addition of 6 SDS-PAGE loading dye. Samples were heated at 85°C for 5
min, resolved using 4 to 12% SDS-PAGE, and imaged with a FujiFilm
FLA-7000 scanner. Phosphor bands were quantified using FujiFilm
MultiGauge software.
Luciferase assays. To examine the effect of siRNA dosage on tran-
scription, 1.2  105 HeLa cells were reverse transfected with various
amounts of siRNA designed against CDK12 or CDK9 using Lipo-
fectamine 2000 (Invitrogen). The negative-control siRNA used in these
experiments was either CDK12 negative-control siRNA (cytomegalovirus
[CMV] transcription experiment using pRL-CMV plasmid [Promega])
or CDK9 negative-control siRNA (simian virus 40 [SV40] transcription
experiment using pGL3-Promoter plasmid [Promega]). Forty-eight
hours after siRNA transfection, 100 ng of reporter plasmid (pRL-CMV or
pGL3-Promoter) expressing luciferase was transfected, and at 72 h after
siRNA transfection, cells were lysed with luciferase lysis buffer (Promega)
and the assay was performed according to the manufacturer’s instruc-
tions. The total protein concentration was determined by Bradford assay.
To determine the dependence of transcription onCDK12 and cyclin K, 10
pmol CDK12 or cyclin K siRNA designed against the 3= UTR of each
transcript was cotransfected with plasmids expressing ectopic 3FLAG-
CDK12 or 3FLAG-cyclin K1, respectively, or an empty vector control.
Forty-eight hours posttransfection, 100 ng of reporter plasmid (pRL-
CMV or pGL3-Promoter) was transfected, and cells were harvested at 72
h posttransfection and assayed for transcription as described above.
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CDK12/CrkRS interacts with a 65-kDa isoform of cyclin K.We
employed IP-MS as an unbiased approach to identify possible cyclin
partners from endogenous CDK12/CrkRS complexes isolated from
HeLa, K562, and HEK293 cells. Mass spectra that matched cyclin K
peptides were identified in SDS-polyacrylamide gel slices corre-
sponding to amolecular-mass range between 60 and 80 kDa (Fig. 1A
andTable 1).Hereinafter,CDK12/CrkRSwill be calledCDK12 for its
association with cyclin K.
To more comprehensively identify cyclin partners of CDK12,
we expressed N-terminally and C-terminally tagged 3FLAG-
CDK12 proteins in HEK293A cells. IP-MS analysis of anti-FLAG-
immunoprecipitated 3FLAG-CDK12 complexes again identi-
fied mass spectra that matched cyclin K peptides in the 60- to
80-kDa gel slices (Fig. 1A and Table 1). No other cyclins were
present in any of our CDK12 immunoprecipitates.
We were intrigued by the reproducibility of our IP-MS exper-
iments in identifying cyclin K peptides within the 60- to 80-kDa
FIG 1 Identification of a novel isoform of cyclin K in CDK12/CrkRS protein complexes. (A) Colloidal Coomassie stain of immunoprecipitated endogenous
CDK12/CrkRS complexes from K562 cells and 3FLAG-CDK12/CrkRS complexes from HEK293A cells. Cyclin K peptides were found in a 65- to 80-kDa gel
slice. (B) MS-MS spectra of a cyclin K1 peptide. (C) Sequence of a human C-terminal cyclin K1 peptide found by MS-MS aligned to the corresponding chicken
and mouse cyclin K peptides. The predicted cyclin boxes and a proline-rich domain of the cyclin K1 isoform are shown in the bar above the alignment.
TABLE 1 CDK12/cyclin K interactions identified by IP-MSa
Sample Cell type
No. of unique peptides/total
no. of peptides (X!Tandem







CDK12 endogenous IP HeLaS3 8/9 (65.0) 2/2 (12.2) —
CDK12 endogenous IP HEK293 20/28 (169.4) 4/7 (29.9) 306 321 DPQQPAQQQQPAQQPK 1.9 Y
375 398 KPPLAAALGEAEPPGPVDATDLPK 3.6 Y
CDK12 endogenous IP K562 16/26 (143.5) 7/8 (55.5) 306 321 DPQQPAQQQQPAQQPK 3.1 Y
336 346 AVVVSPKEENK 1.3 Y
375 398 KPPLAAALGEAEPPGPVDATDLPK 4.9 Y
CDK12-3FLAG anti-
FLAG IP
HEK293A 18/28 (158.6) 2/2 (10.6) —
HEK293A 10/15 (84.3) 1/2 (8.5) —
3FLAG-CDK12 anti-
FLAG IP
HEK293A 24/47 (224.2) 3/4 (18.9) 375 398 KPPLAAALGEAEPPGPVDATDLPK 2.7 Y
450 459 MMKTEGPSYG 1.2 Y
a CDK12/CrkRS complexes were immunoprecipitated, and cyclin K peptides were identified by MS. Cyclin K1-specific peptides were observed in CDK12 immunoprecipitates from
various cell lines. CDK12-3FLAG, C-terminally FLAG-tagged CDK12; 3FLAG-CDK12, N-terminally FLAG-tagged CDK12.
b Individual X!Tandem expected value scores for cyclin K1-specific peptides are shown. Y, yes; —, no cyclin K1-specific peptide detected.
Cheng et al.
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range. Previous studies on cyclin K showed that human cyclin K is
a 43-kDa protein that interacts with CDK9 and is involved in
transcription (17, 23, 39). However, we identified a number of
peptideswhich suggested the existence of a larger isoformof cyclin
K when we searched the MS data against databases that include
translated expressed sequence tags (ESTs) (Fig. 1B and C).
Genomic arrangement of the cyclin K gene (CCNK) and EST data
suggested an alternative isoform of cyclin K similar to mouse and
chicken cyclin K with a predicted molecular mass of 64 kDa
(Fig. 1C). The deduced reference sequence for human cyclin K
isoform 1 (cyclin K1; GenBank accession number NM_
001099402.1) encodes a 580-amino-acid protein with amolecular
mass of 64 kDa that was predicted based on available EST data in
NCBI. Recently, a nominal 70-kDa form of cyclin Kwas identified
by Western blotting using cyclin K antibodies and analysis of
available EST data (6). Cyclin K2 is defined as the original 357-
amino-acid, 43-kDa isoform of cyclin K (GenBank accession
number NM_003858.3). Our IP-MS spectra have identified novel
cyclin K peptides thatmatch the predicted amino acid sequence of
cyclin K1 (Table 1). These peptides were observed on multiple
occasions in CDK12 immunoprecipitates from both endogenous
CDK12 and ectopic 3FLAG-CDK12 complexes. This is the first
protein sequence evidence to support the expression of human
cyclin K1 protein.
CyclinK1 is the predominant isoformof cyclinK.To address
the question of whether each cyclin K isoform is expressed at the
mRNA level, we performed RT-PCR using primers which are
common to the cyclin K1 and K2 open reading frame (ORF) but
differ in the size of the amplification products due to alternative
splicing (Fig. 2A and B). For cyclin K1 and K2, the first 7 exons are
shared but different splice donors in exon 8 and different splice
acceptors in exons 9a (cyclin K1) and 12b (cyclin K2) are used. For
both isoforms, the last 150 bp of exon 12 are shared but, due to a
frameshift, different amino acids are encoded. Sequencing of these
RT-PCR products generated from HeLa mRNA showed that
49/49 clones isolated conformed to the cyclinK1 isoform, suggest-
ing that cyclin K1 was the predominant isoform in HeLa cells.
To address the generality of expression of the cyclin K1 and K2
isoforms, we examined massively parallel short-read RNA-Seq
data frommRNA libraries of various human tumors and cell lines
available at our research center. RNA-Seq data from 38 libraries
across 7 human tissue types were mapped to all possible combi-
nations of known CCNK gene exons and splice sites using the
ALEXA-Seq gene model-based alternative splicing algorithm
(27). There were zero reads for the 8a-12b exon-exon junction
specific for expressing cyclin K2, while the 8b-9a exon-exon junc-
tion used in expressing cyclin K1 exhibited high relative expres-
sion (Fig. 2C). In addition, we used the splice-aware de novo
aligner HMMSplicer (16) to identify any canonical and nonca-
nonical exon-exon junctions involving annotated or novel unan-
notated CCNK gene exons in RNA-Seq data from 570 libraries
across more than 22 human tissue types. CCNK gene exons 1 to 7
are common to the four Ensembl-annotated transcripts (Fig. 2D)
(http://www.ensembl.org/), while the splicing of exon 8 with
downstream exons differentiates the expression of the isoforms;
three different splice donor sites in exon 8 are used in expressing
the four isoforms. In total, 552,300 exon-exon junction readswere
mapped to the CCNK locus. Most of the reads (542,746, 98.3%)
mapped to the canonical junctions defined by the expression of
the cyclin K1 isoform (CCNK-203) (Fig. 2D). The combination of
the exon 8-9 junction with 29,132 reads and the exon 9-11 junc-
tion with 37,014 reads is uniquely specific for the cyclin K1 iso-
form. The junctions that uniquely specify the other three Ensembl
gene predictions each had less than 10 total reads between all 570
libraries. For the CCNK-202 isoform, predicted to encode cyclin
K2, and the CCNK-204 isoform, the exon/intron junctions are
unusual and noncanonical and may represent artifacts. In addi-
tion, each of the cyclin K1-associated junctions was present in 557
to 570 of the 570 total libraries. We conclude that the cyclin K1
isoform is the highly predominant cyclin K isoform present in
human tissues.
There were a total of 3,232 non-cyclin K1-expressing junction
reads (0.6%) in the coding regions of the CCNK locus (exons 2 to
12) which would be predicted to alter the cyclin K reading frame.
All of these junctions are canonical GU-AG intron junctions ex-
cept for one GC-AG intron (8).Many of these junction reads were
observed with just 1 or 2 reads in the libraries in which they were
observed (data not shown) andmay represent sequencing ormap-
ping artifacts. However, 1,841 of these reads (57%) were present
in just two junctions; the junctions with 977 reads and 864 reads
are present in 318 and 273 different libraries, respectively (Fig.
2D). These putative alternative splicing events affect the structure
of the second cyclin box domain (Fig. 2A). These data indicate that
in some human cancers and tissues, significant levels of alternative
splicing of cyclin K transcripts may occur.
Cyclin K1 interacts poorly with CDK9 in endogenous com-
plexes. Previously, it has been shown that cyclin K interacts with
CDK9 and stimulates transcription in a nuclear runoff assay (23,
39). To test this protein-protein interaction, we performed IP-MS
analysis on endogenous CDK9 complexes isolated by immuno-
precipitation ofCDK9 fromHEK293 andHeLa cells.We observed
the presence of cyclin T1 peptides but not cyclin K peptides (Table
2). Next, we ectopically expressed 3FLAG-tagged CDK9 in
HEK293A cells and isolated recombinant CDK9 complexes to an-
alyze the protein constituents by IP-MS. Both N- and C-terminal
3FLAG-CDK9 complexes contained multiple cyclin T1 pep-
tides. In one sample, we were able to detect one unique peptide
each for cyclin T2 and cyclin K. This suggests that cyclin T2 and K
may interact with only a small proportion of CDK9 molecules
within these cells (Table 2).
Cyclin K interacts primarily with CDK12 in endogenous
complexes. Previous studies have reported interactions between
rat Cdk12 and cyclins L1 and L2 thatmodulate alternative splicing
in vitro (9). Cyclin L1 was also shown to interact with CDK13/
CDC2L5 and facilitate alternative splicing (10). Contrary to these
reports, we were unable to detect cyclin L1 or L2 in any of our
endogenous and ectopically expressed CDK12 immunoprecipi-
tates by MS. To better understand which CDKs associate with a
particular cyclin, we ectopically expressed epitope-tagged cyclin
K1, K2, T1, and L1 and performed IP-MS on the isolated cyclin
complexes. IP-MS analysis of 3FLAG-cyclin L1 complexes
showed the presence of CDK11 peptides, confirming previous re-
ports that CDK11 interacts with cyclin L1 (30, 42, 60). However,
we failed to detect anyCDK13/CDC2L5orCDK12peptides in two
replicates of 3FLAG-cyclin L1 immunoprecipitates (Table 3).
Analysis of 3FLAG-cyclinT1 complexes revealed the presence of
CDK9peptides exclusively. Lastly, we found that 3FLAG-tagged
cyclin K1 and K2 both interact predominantly with CDK12, with
only a few unique peptides detected that correspond to CDK13/
CDC2L5 and CDK9 (Table 3). The lower numbers of peptides
Cyclin K1 Is Required for CDK12/CrkRS Kinase Activity
November 2012 Volume 32 Number 22 mcb.asm.org 4695
 o
n

























































































































































K1: ccnK-203, 580 aa


















6 7 8 9 10 11 1251 2 3 4 a b a b c a b a b c
ATG
chr14: 99020000 99025000 99030000 99035000 99040000 99045000 99050000
cyclin box 1 cyclin box 2
Cheng et al.
4696 mcb.asm.org Molecular and Cellular Biology
 o
n








observed for CDK13/CDC2L5 and CDK9 in these ectopically ex-
pressed cyclin K1 and K2 immunoprecipitates suggested that the
number of cyclin K molecules associated with CDK13/CDC2L5
andCDK9 is less than the number of cyclinKmolecules associated
with CDK12.
To validate our IP-MS results, we performed IP-Western blot
experiments using ectopic expression of CDKs and cyclins. Ecto-
pic expression of 3FLAG-CDK9 and dMyc-cyclin K2 showed an
interaction, as previously reported (Fig. 3C) (23, 39). Expression
of 3FLAG-CDK12 in combination with dMyc-cyclin L1 did not
show an interaction even though cyclin K1, K2, and L1 were ex-
pressed at similar levels (Fig. 3A and B). However, expression of
3FLAG-CDK12 in combination with dMyc-cyclin K1 or dMyc-
cyclin K2 showed an interaction between CDK12 and cyclin K1
and betweenCDK12 and cyclinK2 (Fig. 3A). Together, our IP-MS
and Western blot results strongly suggest that CDK12 predomi-
nantly interacts with cyclin K in vivo.
To estimate the relative proportions of the cyclin partners for a
given CDK or the relative proportions of the CDK partners for a
given cyclin, we employed an MS technique called multiple reac-
tion monitoring (MRM) to analyze immunoprecipitates for mul-
tiple specific cyclin or CDK partners. MRM measures the ion in-
tensity of specific fragments from selected peptides (parent ions),
producing ion chromatograms that are proportional to the abun-
dance of the parent peptide; many peptides can be measured si-
multaneously, allowing for multiplex analysis of the relative pro-
portions of different CDK or cyclin populations.MRM analysis of
CDK complexes showed that endogenous or ectopic CDK12 in-
teracts with cyclin K1 and not cyclin K2 or cyclin L1 and that
endogenous or ectopic CDK9 interacts predominantly with cyclin
T1 in HEK293A cells. MRM analysis of ectopic cyclin complexes
in HEK293A cells showed reciprocal results: cyclin K1 interacts
predominantly with CDK12 and CDK13, cyclin T1 interacts with
CDK9 exclusively, and cyclin L1 interacts predominantly with
CDK11. A detailed description of theMRM study can be found in
Figures S1 and S2 in the supplemental material.
The CDK12/cyclin K complex is required to phosphorylate
the C-terminal domain of RNA Pol II in vitro. To investigate the
dependence of CDK12 on cyclin K for phosphorylation of the
RNA Pol II CTD, we performed in vitro CTD phosphorylation
assays using CDK12 protein complexes isolated from cells stably
expressing 3FLAG-CDK12 where we modulated the expression
of cyclinKusing siRNA and ectopic expression. In this cell line, we
determined themRNA levels of CDK12 and cyclin K by qRT-PCR
(see Fig. S3 in the supplemental material). CDK12 expression was
normalized against the control cell line which expresses only en-
dogenous CDK12. The HEK293A/3FLAG-CDK12 stable cell
line typically expresses CDK12 mRNA at levels 9- to 11-fold
higher than the level in the control cell line (see Fig. S3B). We
designed siRNAs against a 3=untranslated region (UTR) shared by
both cyclin K1 and K2. The 3= UTR cyclin K siRNAs proved to be
effective in knocking down cyclin K mRNA levels (60%) in
HEK293A cells as determined by qRT-PCR (see Fig. S3A). We
next proceeded to isolate 3FLAG-CDK12 complexes by immu-
noprecipitation using an anti-FLAG antibody and assaying the
CDK12 protein complex for CTD phosphorylation activity in
vitro. In cells treated with cyclin K siRNAs, we noted a decrease in
CTDphosphorylation that was consistent and significant in 3 rep-
licate experiments (Fig. 4A, lanes 2 and 3, and B). CTD phosphor-
ylation was partially restored or increased with the expression of
FIG 2 Cyclin K1 is the predominant cyclin K mRNA isoform. (A) Cyclin K gene exon arrangement and splicing. The exon arrangement of the CCNK locus on
chromosome 14 is depicted. Splicing pathways that produce a 43-kDa isoform (cyclin K2) and a 64-kDa isoform (cyclin K1) are shown; subdivisions in exons 7,
8, 9, and 12 represent different known splice acceptors and donors observed in the mRNA and EST data. The numbered arrows depict primers and RT-PCR
product sizes that were used to discriminate between the cyclin K1 and K2 isoforms. The 8b-9b (orange) and 8a-12b (red) exon-exon junctions differentiate the
expression of the cyclin K1 and K2 isoforms, respectively. (B) Cyclin K1mRNA is present in HeLa cells. RT-PCR of HeLa poly(A)-enriched RNAwas performed
with primer pairs 1/2 and 3/2 that were designed to differentiate between cDNAs for cyclin K1 and K2 (see panel A). RT-PCR products corresponding to the
predicted size for cyclin K1 are indicated. Sequencing of the 300-bp and 950-bp bands showed that they are not cyclin K related, and they are denoted as
nonspecific (ns). (C) RNA-Seq analysis of known cyclin K exons and exon junctions. The normalized expression of observed combinations of known splice
donors and acceptor sites (Fig. 2A) for theCCNK locus for 38 human cancer and cell linemRNA libraries is shown. (D)Detection of cyclinK exon-exon junctions
by HMMSplicer analysis of RNA-Seq data. Exon-exon junction RNA-Seq read counts (552,300 total) from 570 human cancer and cell mRNA libraries that
mapped to the CCNK locus using HMMSplicer are shown. The junctions putatively connect the exons (vertical gray bars) for the Ensembl-predicted gene
transcripts (red, bottom). Total read count among the 570 libraries for each junction read is shown; in parentheses is the number of libraries where the junction
read was observed. The thickness of each line approximates the relative abundance of the junctions. In the exon 8 region, three different splice donor sites (Fig.
2A) are used between four Ensembl transcripts. The green bars represent the junctions or junction combinations that would uniquely define each of the
Ensembl-predicted isoforms. The number of counts observed for each of the isoform-defining junctions is shown in the right-hand column. For the K1 isoform
(CCNK-203), the isoform-specific read count, 33,073, is the mean of the counts of the two K1-defining junctions (29,132 and 37,014).
TABLE 2 Cyclin interactions of CDK9 identified by IP-MSa
Bait protein Cell line




Endogenous CDK9 HEK293 13/18 (108.5) 0 18/34 (169.3) 0
HeLaS3 15/17 (118.9) 0 4/4 (27.2) 0
3FLAG-CDK9 HEK293A 13/27 (116.2) 0 3/3 (18.4) 0
CDK9-3FLAG HEK293A 15/31 (145.4) 0 11/13 (98.8) 0
HEK293A 23/96 (227) 1/1 (1.4) 12/12 (98.7) 1/3 (18.2)
a Endogenous CDK9 and N-terminally (3FLAG-CDK9) and C-terminally tagged (CDK9-3FLAG) proteins were immunoprecipitated, and the complex was analyzed for cyclin
proteins.
Cyclin K1 Is Required for CDK12/CrkRS Kinase Activity
November 2012 Volume 32 Number 22 mcb.asm.org 4697
 o
n








ectopic dMyc-cyclin K1 (Fig. 4A, lanes 3 and 4, and B). Based on
our results, we conclude that CDK12 can be activated by cyclin K
for phosphorylation of the CTD of RNA Pol II.
To test whether the phosphorylation of the CTD by CDK9 is
dependent on cyclin K, we isolated CDK9 complexes from the
same cells treated with cyclin K siRNAs. Cyclin K siRNA and cy-
clin K1 ectopic expression had little to no effect on CDK9 phos-
phorylation of the CTD (Fig. 4A, lanes 7, 8, and 9). This agrees
with our previous observations that CDK9 interacts predomi-
nantly with cyclin T1 and that CDK9/cyclin K complexes may
constitute a small subset of P-TEFb (positive transcription elon-
gation factor b) complexes within a cell.
We next investigated which serine residues of the CTD heptad
repeat are phosphorylated by CDK12 and whether phosphoryla-
tion of specific serine residues in the CTD by CDK12 is activated
by cyclinK. CDK9has been shown to phosphorylate Ser2 and Ser5
of the CTD heptad repeat (1, 50, 51, 66).We performed an in vitro
CTD phosphorylation reaction using immunoprecipitated
CDK12 complexes isolated from cells treated with negative-con-
trol siRNA or cyclin K siRNA to determine whether the presence
TABLE 3 CDK interactions of cyclin K1, K2, T1, and L1 identified by IP-MSa
Bait protein Cell line
No. of unique peptides/total no. of peptides (X!Tandem score)
Cyclin
CDK:
12 13 (Cdc2L5) 9 11
Cyclin L1-3FLAG HEK293A 4/4 (24.8) 0 0 0 1/1 (1.2)
HEK293A 3/3 (18.7) 0 0 0 9/14 (69.4)
3FLAG-cyclin T1 HEK293A 5/5 (36.7) 0 0 5/6 (33.9) 0
Endogenous cyclin T1 HEK293 1/1 (1.6) 0 0 14/18 (114.3) 0
HeLaS3 11/32 (98.9) 0 0 16/25 (136.3) 0
Cyclin K2-3FLAG HEK293A 12/17 (102.9) 14/16 (112.8) 8/11 (83.8) 0 0
HEK293A 4/4 (29.5) 8/9 (66.6) 1/2 (10.5) 1/2 (7.9)
3FLAG-cyclin K1 HEK293A 16/60 (157.5) 8/14 (66.3) 3/5 (23.1) 0 0
HEK293A 17/92 (187.9) 6/12 (44.8) 1/6 (17.2) 2/6 (17.1) 0
a Endogenous and overexpressed epitope-tagged cyclin complexes were isolated by immunoprecipitation and analyzed by MS for CDKs. Cyclin L1- or K2-3FLAG, N-terminally


















































































FIG 3 Immunoprecipitation-Western blotting validation of CDK12-cyclin K interaction. (A and B) Western blot analyses of anti-FLAG-immunoprecipitated
complexes probed with anti-FLAG and anti-Myc antibodies (A) and of anti-Myc-immunoprecipitated complexes probed with anti-FLAG and anti-Myc
antibodies (B). An asterisk denotes the protein indicated by the arrow on the right. dMyc, 2Myc. (C) dMyc-cyclin K2 was immunoprecipitated with anti-Myc,
and the blots probed with anti-FLAG antibody. Both 3FLAG-CDK12 and 3FLAG-CDK9 interact with dMyc-cyclin K2.
Cheng et al.
4698 mcb.asm.org Molecular and Cellular Biology
 o
n








of cyclin K would have a differential effect on phosphorylation of
Ser2 and Ser5 of the CTD. Like CDK9, CDK12 can phosphorylate
Ser 2 and Ser5 of the CTD (Fig. 4C). We also found that the
phosphorylation of Ser2 and Ser5was potentiated inCDK12 com-
plexes isolated from cells treated with cyclin K siRNA, suggesting
that the phosphorylation of Ser2 and Ser5 by CDK12 is dependent
on the presence of cyclin K in vitro (Fig. 4D).
CDK12 affects gene expression in vivo. Phosphorylation of
RNAPol II CTD canmodulate the transcription of genes and pro-
moter/reporter constructs (29). To determine whether CDK12
can affect the expression of a reporter gene, we transfected HeLa
cells with various doses of siRNA against CDK12 andCDK9. Total
cellular lysates were assayed for the ability to affect the expression
of firefly luciferase (hereinafter Fluc) or Renilla reniformis lucifer-
FIG 4 CDK12 is dependent on cyclin K to phosphorylate the C-terminal domain of RNA Pol II. (A) Cyclin K expression modulates CTD phosphorylation by
CDK12. 3FLAG-CDK12 complexes isolated from cells stably expressing 3FLAG-CDK12 that were modulated with cyclin K siRNA designed against the 3=
UTR of the CCNK gene showed a significant decrease in RNA Pol II CTD phosphorylation compared to the results for the negative control (lane 3 versus lane
2). CTD phosphorylation was restored with the expression of dMyc-cyclin K from an exogenous plasmid (lane 4). Lane 1, a negative-control anti-FLAG IP from
a control cell line not expressing 3FLAG-CDK12; lanes 2 to 9, anti-FLAG-CDK12 or endogenous CDK9 complexes isolated from a cell line stably expressing
3FLAG-CDK12; lane 5, cells were mock transfected with an empty dMyc vector and without siRNA. (B) Graphical representation of the results of 3 replicate
experiments showing CDK12 dependence on cyclin K to phosphorylate RNA Pol II CTD. The vertical range and horizontal mark are the standard deviation and
the mean, respectively. (C) Immunoprecipitated CDK12 and CDK9 phosphorylate Ser2 and Ser5 of the CTD heptad in vitro. “IP” denotes the Western analysis
of the immunoprecipitated complexes used in the CTD assays. (D) siRNA knockdown of cyclin K in CDK12 immunoprecipitates showed a decrease in Ser2 and
Ser5 phosphorylation relative to the results of a control siRNA knockdown.
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ase (hereinafter Rluc) from two different promoters. We found
that Rluc expression from a CMV-driven reporter plasmid signif-
icantly decreased in a CDK12 siRNA dose-dependent manner,
whereas the negative-control siRNA and CDK9 siRNA did not
show a significant siRNA dose-dependent effect (Fig. 5A). Three
different CDK12 siRNA molecules, two designed against the 3=
UTR of the CDK12 gene and one for the ORF, were assayed and
showed similar dose-dependent effects on Rluc gene expression
FIG 5 CDK12 modulates CMV and SV40 promoter-driven transcription. (A and B) SiRNA dose-dependent knockdown by 3 different CDK12 siRNAs and a CDK9
siRNAof transcriptiondrivenbyCMV(A)orSV40(B).Transcription ismeasuredbyRluc (A)orFlu (B)activity. Lines represent theaveragesof3 replicates. Significance
was calculated for the siRNA treatments versus the negative control using the 5 to 40 pmol data with theMann-WhitneyU test [two-sided;P(2)], as follows: in panel A,
* indicates P(2) 0.0002 (CDK12 siRNA-3), ** indicates P(2) 0.0001 (CDK12 siRNA-1 and siRNA-2), and # indicates P(2)	 0.1135; in panel B, * indicates P(2)
0.00011 (CDK12 siRNA-1 and siRNA-3 and ** indicatesP(2)0.0001 (CDK12 siRNA-2 andCDK9 siRNA). (C)Western blots showing examples ofCDK9 siRNAand
CDK12 siRNA-2 knockdown of CDK9 and CDK12 protein expression, respectively. (D) CDK12 siRNAs reduce SV40-mediated transcription. CDK12 siRNA knock-
downof SV40-driven transcriptional activitieswas rescued by ectopic expression ofCDK12. (E)CDK12 siRNA-2 reducesCMV-mediated transcription.CDK12 siRNA
knockdown of CMV transcriptional activities was also rescued by ectopic expression of CDK12. P values indicated are significant (P 0.05) and reproducible across
differentCDK12 siRNAmolecules. (F)Transcription fromtheCMVpromoterwas sensitive to cyclinKexpression, demonstrating thatCDK12wasdependenton cyclin
K for transcriptional activity (P 0.004). (D to F) The vertical range is the standard deviation.
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(Fig. 5A). This suggests that CDK12 protein expression can affect
protein expression from a CMV promoter.
To show that the CDK12 transcriptional effect was not re-
stricted to the CMV promoter, we tested an SV40 promoter driv-
ing the Fluc gene. All threeCDK12 siRNAmolecules decreased the
expression of luciferase from an SV40-driven promoter in a dose-
dependent manner similar to that observed with the CMV-driven
reporter (Fig. 5B). We noted that CDK9 siRNA also decreased the
expression of luciferase in a dose-dependent manner. Western
blot analysis of CDK12 andCDK9 expression after treatment with
siRNA showed that CDK9 and CDK12 protein levels were de-
creased (Fig. 5C). Thus, the siRNA dose-dependent decrease in
SV40-mediated gene expression correlates with decreases in
CDK12 and CDK9 protein expression.
To further test the dependence of CMV-Rluc and SV40-Fluc
expression on CDK12 expression, we sought to restore reporter
expression in CDK12 siRNA-treated cells with the expression of
ectopic CDK12. HeLa cells were independently transfected with
two different CDK12 3=-UTR siRNAs in combination with a plas-
mid expressing ectopic 3FLAG-CDK12 or a control plasmid.
For both promoters, cells cotransfected with CDK12 3=-UTR
siRNAs and a control plasmid showed a significant decrease in
reporter protein expression compared to the expression level in
cells cotransfected with a negative-control siRNA and control
plasmid (Fig. 5D and E). Cells cotransfected with CDK12 3=-UTR
siRNAs and the 3FLAG-CDK12 plasmid showed significant res-
toration of reporter protein activity fromboth promoters (Fig. 5D
and E). These results support our earlier finding that CDK12 spe-
cifically affects protein expression from both CMV and SV40 pro-
moters by demonstrating that the reduction of reporter protein
activity due to CDK12 siRNA treatment can be relieved by the
expression of ectopic CDK12 protein.
We next sought to link CDK12 dependence on cyclin K to its
effect on reporter protein expression. We found that cyclin K 3=-
UTR siRNA treatment significantly decreased CMV-driven re-
porter expression and that reporter expression could be restored
with the addition of ectopically expressed cyclin K1 (Fig. 5F).
Our data convincingly show that cyclin K and CDK12 physi-
cally interact, that both CDK12 and cyclin K can modulate re-
porter gene expression, and that the phosphorylation of RNA Pol
II byCDK12 ismodulated by cyclinK, suggesting that theCDK12/
cyclin K complex directly affects gene expression, possibly
through modulation of RNA Pol II activity by CTD phosphoryla-
tion.
DISCUSSION
We have identified a 65-kDa isoform of cyclin K (cyclin K1) as the
predominant cyclin partner for humanCDK12, previously named
CrkRS. Cyclin K1 is required to activate CDK12 to phosphorylate
Ser2 and Ser5 of RNA Pol II CTD in vitro, and CDK12/cyclin K
affects the expression of two reporter genes under the control of
different promoters.
Truncated cyclin K cDNAs were first identified through yeast
2-hybrid experiments as a cyclin partner for human CDK9 (17,
23). The cyclin K primary structure was subsequently defined as a
357-amino-acid (43-kDa) protein according to a single cDNA
clone (GenBank accession number BC015935) from human uter-
ine tissuemade in a large-scale human cDNA cloning project (59).
This cDNA is currently referred to as cyclin K2. Our analysis of
500,000 RNA-Seq exon-exon junction read sequences mapped
to the CCNK locus from 570 mRNA libraries and more than 22
human tissue types and tumor samples indicated that 99% of
the junction reads are consistent with the expression of the cyclin
K1 isoform primary structure. For the other three isoforms of
cyclin K, none had Ensembl-annotated junction reads supporting
their presence above background levels. RT-PCR analysis of HeLa
cyclin K gene transcripts also exclusively supported the cyclin K1
isoform. Recently, the reference sequence of cyclin K2 (GenBank
accession number NM_003858.3) was suppressed by GenBank
because of poor support and use of nonconsensus splice sites.
Indeed, our inspection of the cyclin K2 entries in EST and cDNA
databases appears to indicate that they were all derived from the
BC015935 clone.We therefore conclude that the 65-kDa cyclinK1
is the predominant cyclin K protein in humans. However, the
RNA-Seq data also indicate that novel alternative splice versions
of cyclin KmRNAsmay exist at low frequencies.Most of the novel
exon junction reads in the ORF alter the primary sequence of the
cyclinK gene in the exon 6 and 7 region, which encodes the second
cyclin box-like domain that forms part of the CDK binding sur-
face in the crystal structure of cyclin K (2). The truncated protein
products predicted from these transcripts may have altered
CDK12 binding properties or function. In addition, there is RNA-
Seq evidence for novel alternative splice events (10%) that affect
the 5= UTR of cyclin K but not the ORF. The existence and bio-
logical significance of these putative novel cyclin K mRNAs re-
main to be investigated. Our analysis shows that querying large
numbers of existing RNA-Seq libraries is a rapid means to com-
prehensively define the structural variants of human mRNAs.
Our MS results are the first observation of cyclin K1 at the
protein sequence level and show no evidence for the existence of
the cyclin K2 protein. Structurally, the 580-amino-acid sequence
of cyclin K1 encodes an 200-amino-acid proline-rich C-termi-
nal region conserved in metazoans that is not present in cyclin K2
(Fig. 1C). Proline-rich protein domains are often sites for the
binding of regulatory proteins (61, 62). We propose that this re-
gion may facilitate cyclin K protein-protein interactions that reg-
ulate CDK12/cyclin K1 function.
CyclinKhas been identified as aCDK9 cyclin partner in several
studies. Ectopic coexpression of CDK9 and cyclin K was shown to
phosphorylate the CTD of RNA Pol II or to modulate transcrip-
tion and gene expression (17, 23, 39). Fusion of cyclin K to Rev
modulates a Rev-responsive promoter/reporter gene (39). These
results led to the inclusion of cyclin K as a cyclin partner for CDK9
in P-TEFb complexes. Several biological functions have also been
attributed to cyclin K and CDK9/cyclin K. Overexpression or
siRNA-mediated knockdown of cyclin K showed that cyclin K
could regulate mesoderm induction in Xenopus laevis and modu-
late replication stress response and genome integrity in human
cells (65, 67). These results were interpreted as cyclin K regulating
CDK9 function based on the presumed association of cyclin K and
CDK9. Using an unbiased approach employing IP-MS of endog-
enous and ectopic CDK12, CDK9, cyclin K1, and cyclin T1 com-
plexes in three human cell lines (HEK293, K562, and HeLa), we
showed that the primary cyclin partner for CDK12 is cyclin K1,
that cyclin K1 predominantly interacts with CDK12 and CDK13,
and that cyclin K1 is not a common cyclin partner for CDK9.
While we do not observe detectable levels of endogenous CDK9/
cyclin K complexes, we cannot rule out this complex at low levels
or in other tissues or biological states. In our experiments with
ectopic expression of CDK9 and cyclin K1, we can force low levels
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of CDK9/cyclin K1 interaction, but these are much lower than the
levels of CDK9/cyclin T1 or CDK12/cyclin K1 complexes. Thus,
the roles of cyclin K in mesoderm induction, replication stress
response, and genomic stability could be interpreted as CDK12/
cyclin K functions. This is further corroborated by a recent study
showing that CDK12/cyclin K complexes helped maintain
genomic stability through regulation of DNA damage response
genes, such as BRCA1, ATR, and FANCI (6). Therefore, previous
functions attributed to cyclin K through a CDK9 interaction
should be interpreted with caution.
Further evidence that CDK9/cyclin K interactions may lack
structural and biological significance is shown by the crystal struc-
ture of the N-terminal region of cyclin K that encompasses the
cyclin box domains (residues 11 to 267) (2). It was noted that the
cyclin K surface on the CDK9 binding interface differed signifi-
cantly from the same interface on cyclin T1. It was hypothesized
that cyclin T1 and K may have different affinities for CDK9. Sim-
ilarly, analysis of the CDK9/cyclin T1 co-crystal structure reveals
that some of the critical cyclin T1 residues involved in binding
CDK9 are different in cyclin K (5). Our data indicate that the
different chemical nature of the interface relates primarily to the
preferential binding of cyclin K to CDK12 or CDK13. This is im-
portant since inhibitors that interfere with CDK9/cyclin T1 or
CDK9/cyclin K binding or P-TEFb kinase activity are being pur-
sued for therapeutic applications in AIDS, heart hypertrophy, and
cancer (2, 52). Our data suggest that CDK9-, cyclin K-, and P-
TEFb-based inhibitors may also modulate functions associated
with CDK12 or CDK13.
Rat Cdk12 and mouse Cdk13 have previously been shown to
interact with cyclin L1, an RS domain-containing cyclin known to
be involved in splicing (9, 10, 14, 42). These studies were per-
formed using ectopic coexpression of rat Cdk12 or mouse Cdk13
with rat cyclin L. It was shown that rat cyclin L1 enhanced the
alternative splicing of a model pre-mRNA splicing substrate (9,
10). We did not detect cyclin L1 in any of our CDK12 immuno-
precipitates by IP-Western blotting, MS-MS, or MRM. However,
we did detect cyclin L1 in endogenous CDK11 immunoprecipi-
tates and CDK11 in ectopic 3FLAG-cyclin L1 immunoprecipi-
tates using both MS-MS and MRM. These data indicate that
CDK11 and cyclin L1 interact primarily with each other. CDK11
has been shown to interact with cyclin L1 and L2 to differentially
affect splicing in vivo (42). We cannot rule out that CDK12 and
CDK13 interact with cyclin L1 in vivo at low levels or in other
tissues or biological states; however, this interactionwas below the
limits of our detection methods. Our results argue that cyclin K1
and not cyclin L1 is the primary cyclin partner of CDK12 and
CDK13. This observation was further corroborated by a recent
publication (6). We propose that, because both CDK12 and
CDK13 contain their own RS domain, they do not need the RS
domain in cyclin L1 to function in the spliceosome and that cyclin
K1 may be required to activate CDK12 and CDK13 for splicing
functions in addition to their kinase functions.
Recently, it was reported that a 70-kDa cyclin K interacts with
CDK12, that CDK12/cyclin K affects the expression of DNA dam-
age response genes, and that CDK12 affects Ser2 and Ser5 phos-
phorylation of RNA Pol II CTD in vivo (6). However, the report
did not show a functional dependence of CDK12 on cyclin K for
these activities. In addition to clarifying cyclin K1’s structure and
its CDK interactions, we have demonstrated that cyclin K1 can
activate CDK12 CTD kinase activity and that immunoprecipi-
tated complexes of CDK12 were able to phosphorylate Ser2 and
Ser5 of RNAPol II CTD in vitro in a cyclin K1-dependentmanner.
Whether CDK12 phosphorylates Ser5 in vivo remains to be exam-
ined (although knockdown of Drosophila Cdk12 in vivo did not
result in lower levels of phosphorylated Ser5) (4). We cannot rule
out the possibility that human CDK12 can phosphorylate other
residues, such as Ser7, or only specific heptads in the 52-heptad
repeat of the human RNA Pol II CTD.
Using CMV and SV40 promoter reporter assays, we showed
that CDK12 modulated the expression of genes driven by two
different promoters and that cyclin K1 also modulated CMV-
driven reporter gene expression. Combined, our data show that
theCDK12/cyclinK1 complex can phosphorylate Ser2 and Ser5 of
RNA Pol II CTD, that CDK12/cyclin K can affect gene expression
fromdifferent promoters, and that both these activities are depen-
dent on cyclin K expression. Interestingly, we observed that CDK9
only modulated reporter gene expression from the SV40 pro-
moter, whereas CDK12modulated reporter gene expression from
both SV40 and CMV promoters. Previous studies show that
CDK9 and CDK12 have distinct differences in localization within
the cell nucleus, suggesting different activities (4). These observa-
tions are consistent with the functional differences between the
yeast Bur1 and Ctk-1 complexes, the homologues of CDK9 and
CDK12, respectively (28, 41). The Bur1 complex has been shown
to phosphorylate Rad6 to regulate histone H2B monoubiquitina-
tion, which is associated with transcriptionally active chromatin
(31). Likewise, CDK9 has been shown to interact with and phos-
phorylate UBE2A to regulate H2B monoubiquitination (54). In
yeast, the Ctk-1 complex is the major RNA Pol II CTD serine 2
kinase and is involved in the recruitment of histone methyltrans-
ferase Set2 and other transcription factors during the mid- and
late elongation phases of gene transcription (33, 36). Similarly,
Cdk12 has been shown to phosphorylate serine 2 both in vitro and
in vivo and appears to be associated with transcription elongation
(4). Thus, CDK12/cyclin K and CDK9/cyclin T1 complexes may
have different roles in regulating RNA Pol II transcription.
Further exploration of the functions of CDK12 and CDK13 are
needed to identify CDK12-/CDK13-associated functions, as
well as some previously attributed to CDK9, which could have
broad relevance in the control of many cellular processes and
diseases.
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